The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.

Following in the wake of Merck & Co's acquisition of VelosBio, the German major is spending big to get hold of the Swiss oncology biotech NBE-Therapeutics which is also targeting the ROR1 protein.

The German pharma’s top business development execs explain how they balance IO and targeted cancer therapy in their portfolio, views on major M&A and how to make deals during a global pandemic.

AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.